Drug Profile
GRI 0621
Alternative Names: GRI-0621Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator GRI Bio
- Class Antifibrotics; Hepatoprotectants; Small molecules
- Mechanism of Action Natural killer T cell inhibitors; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
- Discontinued Liver disorders
Most Recent Events
- 16 Apr 2024 GRI Bio receives notice of patent grant for GRI 0621 in South Korea
- 14 Mar 2024 GRI Bio receives patent allowance for GRI 0621 in Canada
- 04 Mar 2024 GRI Bio receives CTA authorization from the UK MHRA for the initiation of phase IIa biomarker study for the treatment of idiopathic pulmonary fibrosis